🇺🇸 FDA
Patent

US 11202819

Use of C-type natriuretic peptide variants to treat osteoarthritis

granted A61KA61K31/573A61K31/728

Quick answer

US patent 11202819 (Use of C-type natriuretic peptide variants to treat osteoarthritis) held by BIOMARIN PHARMACEUTICAL INC. expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BIOMARIN PHARMACEUTICAL INC.
Grant date
Tue Dec 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K31/573, A61K31/728, A61K38/22, A61K38/2242